Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

neuroinflammatory inhibitor MW151

An orally bioavailable central nervous system (CNS)-penetrant and inhibitor of certain inflammatory mediators, with potential neuroinflammation attenuating and neuroprotective activities. Upon oral administration, MW151 is able to penetrate the blood-brain-barrier (BBB) and inhibits the up-regulation of certain neuroinflammatory responses upon brain injury or caused by certain diseases. MW151 suppresses neuroinflammation-induced glial activation and prevents the production of certain pro-inflammatory cytokines, such as interleukin-1 beta (IL-1b) and tumor necrosis factor alpha (TNFa). By preventing the overproduction of inflammatory cytokines, over-activated neuroinflammatory pathways are attenuated and associative damage is decreased. This may slow down or prevent certain neurodegenerative disease and cognitive impairment. MW151 may also prevent damage to synapses and synaptic plasticity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-neuroinflammatory agent MW151
US brand name:Minozac
Code name:MW 151
MW-151
MW01-2-151SRM
MW151
Chemical structure:2-(4-(4-methyl-6-phenylpyridazin-3-yl)piperazin-1-yl)pyrimidine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search